Furthermore, the three IL-17R subunits, corresponding to the IL-17E (IL17RA/RB) and IL-17A (IL17 RA/RC) receptors, were highly upregulated in tumor versus normal samples, suggesting that IL-17E as IL-17A signaling is potentially active in human breast cancer. This evidence concerns the gene IL25 and breast cancer.